Advanced

Clinical outcomes and resource utilization associated with haemophilia care in Europe

Schramm, W; Royal, S; Kroner, B; Berntorp, Erik LU ; Giangrande, P; Ludlam, C; Gringeri, A; Berger, K and Szucs, T (2002) In Haemophilia 8(1). p.33-43
Abstract
We conducted a multicentre, cross- sectional study of 1042 haemophilia subjects across Europe to compare various health outcomes associated with on-demand vs. prophylactic factor-substitution therapy. Demographic, medical history, and healthcare resource utilization data were analysed along with the number of bleeding events over the past 6 months. Treatment-cost data were also examined to provide preliminary information for future economic studies. A logistic regression analysis, controlling for other statistically significant covariates, showed that patients treated on demand were 3.4 times more likely to have had a joint bleed over the previous 6 months than those treated with prophylaxis. Multiple regression analyses further confirmed... (More)
We conducted a multicentre, cross- sectional study of 1042 haemophilia subjects across Europe to compare various health outcomes associated with on-demand vs. prophylactic factor-substitution therapy. Demographic, medical history, and healthcare resource utilization data were analysed along with the number of bleeding events over the past 6 months. Treatment-cost data were also examined to provide preliminary information for future economic studies. A logistic regression analysis, controlling for other statistically significant covariates, showed that patients treated on demand were 3.4 times more likely to have had a joint bleed over the previous 6 months than those treated with prophylaxis. Multiple regression analyses further confirmed these findings, because on-demand subjects had, on average, 5.15 more joint bleeds over the reporting period than patients treated with prophylaxis. Notably, these findings were even more dramatic for younger haemophilia patients when our study sample was stratified by age. Due to the high cost of factor replacement, healthcare costs were significantly higher for subjects treated prophylactically. While hospital costs for prophylaxis subjects were, on average, lower, statistically significant cost savings for prophylactic subjects were not noted. These results suggest that clinicians and health policy decision-makers should consider the advantages of prophylactic therapy for haemophilia patients in formulating treatment protocols and allocating health resources. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
clinical outcomes, on-demand factor substitution, haemophilia care, resource utilization, prophylactic factor substitution
in
Haemophilia
volume
8
issue
1
pages
33 - 43
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • pmid:11886463
  • wos:000174696500006
  • scopus:0036210038
ISSN
1351-8216
DOI
10.1046/j.1365-2516.2002.00580.x
language
English
LU publication?
yes
id
db1ee87b-a38a-4b69-812d-27e1fcce70a7 (old id 893648)
date added to LUP
2008-01-21 08:53:23
date last changed
2017-10-22 03:44:38
@article{db1ee87b-a38a-4b69-812d-27e1fcce70a7,
  abstract     = {We conducted a multicentre, cross- sectional study of 1042 haemophilia subjects across Europe to compare various health outcomes associated with on-demand vs. prophylactic factor-substitution therapy. Demographic, medical history, and healthcare resource utilization data were analysed along with the number of bleeding events over the past 6 months. Treatment-cost data were also examined to provide preliminary information for future economic studies. A logistic regression analysis, controlling for other statistically significant covariates, showed that patients treated on demand were 3.4 times more likely to have had a joint bleed over the previous 6 months than those treated with prophylaxis. Multiple regression analyses further confirmed these findings, because on-demand subjects had, on average, 5.15 more joint bleeds over the reporting period than patients treated with prophylaxis. Notably, these findings were even more dramatic for younger haemophilia patients when our study sample was stratified by age. Due to the high cost of factor replacement, healthcare costs were significantly higher for subjects treated prophylactically. While hospital costs for prophylaxis subjects were, on average, lower, statistically significant cost savings for prophylactic subjects were not noted. These results suggest that clinicians and health policy decision-makers should consider the advantages of prophylactic therapy for haemophilia patients in formulating treatment protocols and allocating health resources.},
  author       = {Schramm, W and Royal, S and Kroner, B and Berntorp, Erik and Giangrande, P and Ludlam, C and Gringeri, A and Berger, K and Szucs, T},
  issn         = {1351-8216},
  keyword      = {clinical outcomes,on-demand factor substitution,haemophilia care,resource utilization,prophylactic factor substitution},
  language     = {eng},
  number       = {1},
  pages        = {33--43},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Clinical outcomes and resource utilization associated with haemophilia care in Europe},
  url          = {http://dx.doi.org/10.1046/j.1365-2516.2002.00580.x},
  volume       = {8},
  year         = {2002},
}